Allogene Therapeutics (NASDAQ:ALLO) Earns Outperform Rating from Royal Bank of Canada

Royal Bank of Canada reaffirmed their outperform rating on shares of Allogene Therapeutics (NASDAQ:ALLO) in a research report released on Friday, Benzinga reports. They currently have a $10.00 target price on the stock.

Several other equities analysts also recently issued reports on the stock. JMP Securities reissued a market perform rating on shares of Allogene Therapeutics in a report on Friday, January 5th. Guggenheim downgraded shares of Allogene Therapeutics from a buy rating to a neutral rating in a report on Friday, January 5th. Citigroup started coverage on shares of Allogene Therapeutics in a report on Friday, December 8th. They issued a buy rating and a $7.00 price objective for the company. JPMorgan Chase & Co. reduced their price objective on shares of Allogene Therapeutics from $9.00 to $8.00 and set an overweight rating for the company in a report on Tuesday, February 27th. Finally, HC Wainwright reduced their price objective on shares of Allogene Therapeutics from $12.00 to $10.00 and set a buy rating for the company in a report on Friday, January 19th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of Moderate Buy and an average price target of $12.45.

Allogene Therapeutics Trading Down 10.0 %

Allogene Therapeutics stock traded down $0.46 during mid-day trading on Friday, reaching $4.20. The company’s stock had a trading volume of 3,031,157 shares, compared to its average volume of 2,957,481. The firm has a market cap of $705.93 million, a price-to-earnings ratio of -2.01 and a beta of 0.81. The business has a 50 day moving average price of $4.20 and a 200-day moving average price of $3.49. Allogene Therapeutics has a twelve month low of $2.23 and a twelve month high of $6.89.

Institutional Trading of Allogene Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ALLO. McGlone Suttner Wealth Management Inc. acquired a new stake in Allogene Therapeutics during the 4th quarter worth about $27,000. EP Wealth Advisors LLC acquired a new position in shares of Allogene Therapeutics in the 3rd quarter valued at about $34,000. Aaron Wealth Advisors LLC acquired a new position in shares of Allogene Therapeutics in the 4th quarter valued at about $34,000. Axxcess Wealth Management LLC acquired a new position in shares of Allogene Therapeutics in the 4th quarter valued at about $34,000. Finally, GTS Securities LLC acquired a new position in shares of Allogene Therapeutics in the 3rd quarter valued at about $35,000. Institutional investors and hedge funds own 78.51% of the company’s stock.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.